Titan Securities Reports Rs 2.79 Cr Consolidated Profit; CFO Resigns

Titan Securities Ltd announced its financial results for the quarter and year ended March 31, 2026. The company reported a consolidated profit of ₹2.79 crore (279.26 lakh).
Consolidated profit: ₹2.79 crore (279.26 lakh), Standalone profit: ₹0.41 crore (40.73 lakh).

Reader Takeaway: Associate profits drive consolidated earnings; CFO transition nears.

What just happened

Titan Securities Ltd reported a consolidated profit of ₹2.79 crore for the quarter and year ended March 31, 2026. Standalone profit stood at ₹0.41 crore. The company's revenue was ₹2.81 crore on both standalone and consolidated bases. A significant portion of the consolidated profit, ₹2.39 crore, came from the 'Share in profit of associate'. Additionally, Mrs. Darshana Santoshi resigned as Chief Financial Officer, effective May 30, 2026, due to personal reasons.

Why this matters

Investors will note the substantial difference between standalone and consolidated profitability, highlighting the importance of associate companies to Titan Securities' overall financial performance. The CFO's resignation also marks a key management change that could influence future financial strategies and reporting. The company's auditors provided an unmodified opinion on the financial statements.

The backstory

The company has also reassessed its investment in Peptech Biosciences Ltd, changing its classification from a 'passive investment holding' to a 'strategic business interest.' This led to a change in its measurement basis from fair value to cost.

What changes now

The company will need to appoint a new CFO to oversee its financial operations. The accounting change for the Peptech Biosciences Ltd investment will impact how its value is reflected in future financial statements. The appointment of Mr. Pankaj Kumar Gupta as Scrutinizer for the upcoming 34th Annual General Meeting is also a procedural update.

Risks to watch

Over-reliance on profits from associate companies for consolidated results could be a risk. The transition to a new CFO might also introduce a period of adjustment for financial management.

Peer comparison

(Information not available in the filing)

Context metrics (time-bound)

• Consolidated Profit Q4 FY26: ₹2.79 crore
• Standalone Profit Q4 FY26: ₹0.41 crore
• Consolidated Revenue Q4 FY26: ₹2.81 crore
• Standalone Revenue Q4 FY26: ₹2.81 crore
• CFO Resignation Date: May 30, 2026

What to track next

Investors should monitor the company's progress in appointing a new CFO and any subsequent financial reporting changes related to the Peptech Biosciences Ltd investment. Performance of associate companies will also be crucial to watch.